Skip to main content
. 2010 Mar 3;10:44. doi: 10.1186/1471-2334-10-44

Table 1.

Demographic, clinical and laboratory characteristics of the study subjects.

Cases
(n = 10)
Control 1a
(n = 17)
Control 2b
(n = 35)
Median Age, years (Range) 35 (9 - 89) 43 (19 - 75) 63 (28 - 81)

Male gender (%) 8 (80.0) 13 (76.5) 24 (68.6)

Allogenic stem-cell transplantation (%) 2 (20.0) 8 (47.1) 0 (0.0)

Neutropenia (%) c 9 (90.0) 11 (64.7) 0 (0.0)

Serum galactomannan testing:
- Number tested (%) 10 (100.0) 11 (64.7) 1 (2.9)
- Median OD index (range)d 0.3 (0.1 - 1.8) 0.1 (0.0 - 0.2) 0.2

BAL galactomannan testing:
- Median OD index (range) 4.1 (1.1 - 7.7) 0.2 (0.1 - 1.0) 0.4 (0.1 - 1.1)
- OD index ≥ 0.5 (%) 10 (100) 3 (17.6) 11 (31.4)

BAL fungal cultures (%): 10 (100) 17 (100) 18 (51.4)
- Candida spp. (%) 1 (10.0) 6 (35.3) 6 (33.3)
- Aspergillus spp. (%) 1 (10.0) 0 (0.0) 0 (0.0)

Primary pulmonary diagnoses:
- IPA (%) 10 (100.0) 0 (0.0) 0 (0.0)
- Bacterial pneumonia (%) 0 (0.0) 4 (23.5) 14 (40.0)
- Lung cancer (%) 0 (0.0) 0 (0.0) 12 (34.3)
- Graft vs. host disease (%) 0 (0.0) 5 (29.4) 0 (0.0)
- Viral pneumonitis (%) 0 (0.0) 2 (11.8) 0 (0.0)
- Interstitial lung disease (%) 0 (0.0) 0 (0.0) 3 (8.6)
- Others (%) 0 (0.0) 6 (35.3) 6 (17.1)

a Controls with underlying hematological diseases meeting EORTC/MSG host factors criteria for invasive fungal disease [3].

b Controls with no underlying hematological diseases.

c Absolute neutrophil count < 500/mm3

d Highest serum galactomannan OD index within two weeks of bronchoscopy, if test was performed.